Abstract
The connective tissue formed by extracellular matrix (ECM) rich in fibronectin and collagen consists a barrier that cancer cells have to overpass to reach blood vessels and then a metastatic site. Cell adhesion to fibronectin is mediated by αvβ3 and α5β1 integrins through an RGD motif present in this ECM protein, thus making these receptors key targets for cell migration studies. Here we investigated the effect of an RGD disintegrin, DisBa-01, on the migration of human fibroblasts (BJ) and oral squamous cancer cells (OSCC, SCC25) on a fibronectin-rich environment. Time-lapse images were acquired on fibronectin-coated glass-bottomed dishes. Migration speed and directionality analysis indicated that OSCC cells, but not fibroblasts, showed significant decrease in both parameters in the presence of DisBa-01 (1μM and 2μM). Integrin expression levels of the α5, αv and β3 subunits were similar in both cell lines, while β1 subunit is present in lower levels on the cancer cells. Next, we examined whether the effects of DisBa-01 were related to changes in adhesion properties by using paxillin immunostaining and total internal reflection fluorescence TIRF microscopy. OSCCs in the presence of DisBa-01 showed increased adhesion sizes and number of maturing adhesion. The same parameters were analyzed usingβ3-GFP overexpressing cells and showed that β3 overexpression restored cell migration velocity and the number of maturing adhesion that were altered by DisBa-01. Surface plasmon resonance analysis showed that DisBa-01 has 100x higher affinity for αvβ3 integrin than forα5β1 integrin. In conclusion, our results suggest that the αvβ3 integrin is the main receptor involved in cell directionality and its blockage may be an interesting alternative against metastasis.
Introduction
Oral squamous cell carcinoma (OSCC) is responsible for 90% of all oral cancers occurring at different sites of the oral mucosa [1, 2]. The exposure to chemical, physical or biological agents with mutagenic and carcinogenic properties leads mutated keratinocytes to proliferate and invade the connective tissue. OSCCs responsiveness to chemotherapy is low likely due to the heterogeneity of tumor cell population; the high local recurrence rate of this disease results in a 5 year survival rate of only 40–50% [2, 3].
Tumor cell migration is pivotal step in invasion and metastases. The change from a non-migratory to a migratory phenotype results in detachment from the primary tumor, invasion into the surrounding tissues, and entry into blood and lymph vessels [4, 5]. Throughout this process, epithelial-derived tumor cells need to adapt to the changing environment, reflecting the change from a laminin-enriched basal membrane to a connective tissue rich in fibronectin and collagen. Previous studies showed that more aggressive OSCCs correlate with increased presence of fibronectin throughout the tissue, particularly at the invasion front [6, 7], which might result in a fast single-cell migration mode [8].
Cell migration is a complex and cyclic process mediated by adhesion molecules such as the integrin receptors [9–11]. They are composed of two different subunits, α and β which may assemble into 24 differently combined heterodimers with individual specificities to ECM proteins. Although some integrins share affinity to the same ligands, they may trigger different signaling pathways [12–14] such as the integrins α5β1 and αvβ3 that bind to fibronectin through a RGD (arginine-glycine-aspartic acid) motif but differentially regulates adhesion maturation [15, 16]. Therefore, the use of peptides that bind to integrins could be considered a strategy to impair cell motility and decrease the possibility of metastasis.
Therefore, the blockage of integrin activity affects several adhesion dependent processes as migration, proliferation, apoptosis, among other processes [17–21]. For instance, disintegrins, a family of low molecular weight, cysteine-rich peptides discovered in snake venoms were found to cause platelet aggregation inhibition, by binding to the integrin αIIbβ3 [22, 23]. DisBa-01 (disintegrin of Bothrops alternatus) is a recombinant RGD containing disintegrin that inhibits cell migration [24], in vivo angiogenesis [25], pulmonary metastasis [26] and is able to decrease the expression of VEGF receptors in endothelial cells [27]. Since ECM components are able to modify the adhesion properties of tumor cells and elicit a migratory behavior [28], we hypothesized that the selective blockage of integrin receptors by an RGD disintegrin might impair the migratory process of OSCC cells on a fibronectin enriched environment.
In this study, we show that DisBa-01 decreased migration speed, directionality and changed the migration mode of a highly invasive OSCC cell line from single to collective cell migration but had no effect on fibroblasts. This selective effect on epithelial-derived tumor cells was accompanied by a modulation of adhesion dynamics and was rescued by the overexpression of β3 integrin. Together, these data strongly suggest thatαvβ3 integrin is the major receptor involved in cell speed and directionality of OSCCs and it can be a critical target for therapy against metastasis.
Material and methods
DisBa-01 expression and purification
DisBa-01 is a recombinant disintegrin produced from a cDNA venom gland library of B. alternatus, since the native disintegrin could not be purified from the venom due to low yields in protein preparations [26]. The coding region corresponds to an RGD containing motif disintegrin of 78 amino acids residues (GenBank accession AY259516). Expression and purification of the recombinant His-tag protein were performed as previously described [26]. Molecular modeling and adhesion assays suggested that the fusion His-tag peptide was not involved on integrin binding and therefore its proteolytic removal would not be needed [26–27].
Cell culture and transfection
SCC25 cells (ATCC1 CRL-1628™) were grown in DMEM/F12 with 15mM HEPES and 0.5mM sodium pyruvate (Gibco), FBS 10% and hydrocortisone (400ng/ml, Sigma), while BJ cells (ATCC® CRL2522™) in DMEM Glutamax with 1% non-essential amino acids (NEAA) and 10% fetal bovine serum. Cal27 (ATCC1 CRL-2095™) were cultivated in DMEM high glucose (Gibco) supplemented with 10% Fetal Bovine Serum (FBS). All cells were maintained in incubator at 37°C and 5% CO2. SCC25 cell was considered a highly aggressive oral squamous cell carcinoma (OSCC) cell line due to its low E-cadherin content when compared to Cal27, an OSCC cell line considered to be minimally invasive [28]. For Total Internal Reflectance Fluorescence (TIRF) microscopy, SCC25 were transfected using TransIT-2020 (Mirus) 24hs before the experiment with 0.5μg of paxillin-GFP plasmid [29]. For β3 subunit overexpression studies, cells were transfected with 0.5μg β3-GFP and 0.5μg paxillin-mko.
Migration and adhesions dynamics assays
Both assays used 3cm glass-bottomed dishes containing fibronectin (2μg/mL) and/or DisBa-01 (1 and 2μM) as a substrate or diluted in the media. Cells were plated with serum free media (CCM1, Thermo Fisher Scientific) and left in the incubator at 37°C for 1 hour (phase microscopy) or 20 min (TIRF microscopy) before imaging. At least 3 different experiments were performed for each group.
For time-lapse phase microscopy, images were acquired from either: BJ (human fibroblasts) and SCC25 (OSCC) over 8 hours with a 10 minute interval, at 37°C using a Nikon TE300 microscope (10x 0.25 NA CFI Achro DL106 Nikon objective), with a charge coupled device camera (Orca II, Hamamatsu Photonics, Iwata-City, Japan) using Metamorph software (Molecular Devices), as previously described [30]. Image J software in manual tracking was used to analyze migration parameters. Migration speed was determined by the ratio between the total distance and duration of cell migration; while directionality was determined by X and Y coordinates normalized to a “zero” starting point.
For time-lapse movies on TIRF microscopy, only the SCC25 cell was used. Images were captured every 3 seconds over 20 minutes using an Olympus IX70 inverted microscope (63x 1.45 NA oil Olympus PlanAplo 660 TIRFM objective), fitted with a Ludl modular automation controller (Ludl Electronic Products), a charge-couple device camera (RetigaExi, Qimaging), and Metamorph software. GFP was excited using the 488nm laser line of an Argon laser (Melles Griot), a dichroic mirror (HQ485/30) and an emission filter (HQ525/50). To estimate the rate of adhesion maturation, nascent adhesions were identified as the adhesions formed at the border of the cell membrane during protrusion and mature adhesions were identified as those that persisted through membrane protrusion, growing in size and elongating.
Additionally, invasion assays were made using 24-well plate Matrigel™ invasion chambers (Corning). DMEM/F12 medium with 5% FBS was pipetted into the wells, except on the negative control where serum-free F12 medium was used. SCC-25 cells (1 x 105 cells) were treated with 1000 nM or 2000 nM DisBa-01 on serum-free F12 medium for 30 minutes. After that, the membrane-containing chamber was added to the well and treated or not-treated cells were applied. The invasion occurred for 48 hours at 37°C. The chamber membrane was fixed in 4% paraformaldehyde and cell nucleus was stained using DAPI. Membranes were assembled in slides using Vectashield® mounting media (Vector Laboratories) and cell count was performed on automated fluorescence microscope system, ImageXpress Micro (Molecular Devices).
Western blots
Cells were trypsinized, washed and lysed in RIPA Buffer (25mMTris-HCL pH 7.6, 150mM NaCl, 1% NP-40, 1% sodium deoxycholate, 0.1% SDS) with protease (P8340, Sigma Aldrich) and phosphate cocktails (P8340, Sigma Aldrich). The lysates were separated by 4–20% precast polyacrylamide gel (BioRad) and proteins transferred to PVDF membranes (BioRad), blocked for 1 hour with 5% defatted milk in a PBS/0.5% Tween 20 at room temperature. Samples were immunoassayed for αv, β3, α5, β1, E-cadherin, N-cadherin and α-Tubulin (Cell Signaling, USA) using Pierce ECL Western Blotting Substrate (Thermo Scientific).
Immunofluorescence
Cells were incubated with DisBa-01 for 3 hours on fibronectin (2μg/ml) covered glass coverslips on CCM1 media. Then, cells were washed with PBS, fixed with formaldehyde 4%, and permeabilized using TritonX-100 (0.3%). Nonspecific binding sites were blocked with normal goat serum, and the cells incubated overnight with anti-paxilin antibody (BD Bioscience). After washing, cells were incubated with secondary antibodies against mouse bound to Alexa488 dye (Molecular Probes, Oregon, USA) and the actin filaments were marked with phalloidin conjugated to rhodamine (Molecular Probes, Oregon, USA). Images were obtained on a confocal microscope (Olympus FluoView 1000, Tokyo, Japan) with the 63x objective (UPlanSApo x63, 1.20 NA, oil immersion objective). Alexa488 was excited via the 488nm line of an Ar laser (Melles Griot, Albuquerque, NM), and rhodamine via the 543nm line of a Helium-Neon laser (Melles Griot, Albuquerque, NM). Images were acquired using FluoView software (Olympus, Tokyo, Japan). The Z-stacks were acquired from cells using 3 0.1μm step size slices (0.3μm of the cell) that were merged using the ImageJ software tool “Z-stack/sum”.
Surface plasmon resonance (SPR)
The affinity of DisBa-01 to immobilized integrins was measured using SPR (BIAcore T200; GE Healthcare, Little Chalfont, UK). α5β1 and αVβ3 integrins (R&D, Minneapolis, MN, USA) were covalently attached via amine coupling (pH Scouting) to sensor chip CM5(GE Healthcare, Little Chalfont, UK). The bound ligand was then perfused in buffer containing 0.01 M Hepes, pH 7.4, 0.15 M NaCl, and 0.005 (v/v) Surfactant P20 (HBS–EP) at 25°C and flow rate of 30 μL/min. Association and dissociation constant rates were calculated by curve fitting, using BIA evaluation 1.1 software, assuming that DisBa-01 is monomeric with a MR of 12,000 Da. After testing the sensor chip in a pH gradient (pH Scouting), integrins α5β1 (pH 4.5) and αVβ3 (pH 4.0) were immobilized onto the sensor chip to get a 4,325.2 RU (Resonance Unit) and a 6,677.1 RU, respectively. Chip regeneration was done by injection of Gly HCl 2M, pH 2.0 for 10s. DisBa-01 (0.1–100 μM) was injected at increasing concentrations onto the sensor chip with both immobilized integrins and the association constant between DisBa–01 and the integrins was calculated via GraFit 5.0 software.
Statistical analysis
One way analysis of variance (ANOVA) was used followed by Tukey´s post test and student t-test for the TIRF microscopy assays.
Results
DisBa-01 selectively affects OSCC migration
As shown in our previous work, DisBa-01 inhibits cancer cell and fibroblast migration using a transwell migration assay [24]. Therefore, to investigate its potential effect on cell migration in a fibronectin rich environment we used two human cell lines that exhibit single cell migration: fibroblasts (BJ) and a highly invasive/low differentiated oral squamous carcinoma cell line (SCC25).Time-lapse movies (8h) were performed on both cell lines plated on glass-bottomed dishes coated with fibronectin (2μg/ml) in the presence/absence of DisBa-01 (1 or 2μM) in the media or in the substrate. Individual migratory cells were tracked and analyzed for migration speed and directionality (total net translocation from the origin point). The fibroblasts (n = 3 experiments) were not detectably affected by DisBa-01, even at a high concentrations (2μM) when compared with control cells (Fig 1A, S1 Movie). However, the OSCC migration speed decreased by ~40% (n = 3 experiments, p<0.0001) when plated in the presence of similar amounts of DisBa-01. This effect was more pronounced for migration directionality (Fig 1B, S2 Movie). While OSCC plated only in fibronectin exhibited a fast, individual and directionally persistent migration behavior, cells treated with 1μM of DisBa-01 in the media or in the substrate lost their directionality and moved in circles with a tendency to migrate in pairs (collectively). This selective effect of DisBa-01 in the tumor cells migration may reflect a differential effect on cell-ECM adhesive properties.
DisBa-01 modulates cells adhesive properties of OSCC
We studied whether DisBa-01effects arose from altered adhesion by immunostaining OSCCs and fibroblasts for paxillin, a marker for nascent adhesions [31].Fibroblasts have small adhesions at the cell border, which are present in rapidly migrating but not stationary cells. DisBa-01 showed no alterations on paxillin distribution for these cells (Fig 2A). In contrast, significant changes were observed in the adhesions in OSCCs, including an increase in the size and number of adhesions in the presence of DisBa-01 in the media or in the substrate when compared to cells plated only on fibronectin (Fig 2B).
To further investigate the adhesion dynamics seen at the paxillin immunostaining, SCC25 cells were transfected with paxillin-GFP and plated on fibronectin coated dishes (2μg/mL) 24h later in the presence/absence of DisBa-01 in the media or in the substrate. Then, maturation rate was imaged on TIRF microscopy every 3 seconds during 20 minutes. DisBa-01 increased the rate of adhesion maturation and the average area of each adhesion in OSCCs (Fig 2, S3 Movie). During the migration process, cells extend their membrane to form the lamellipodia and then attach the membrane to the extracellular matrix. The area of these protruding membranes was also measured and it was ~3x larger in DisBa-01 treated OSCC than control cells (n = 3 cells, p>0.0005). Taken together, these data show that DisBa-01exhibits a differential cell type dependent effect on cell adhesion properties.
Fibronectin is a glycoprotein found on the ECM that interacts mainly with integrins αvβ3 and α5β1 through the RGD motifs in its structure [15, 32]. A possible mechanism for the differential effects of DisBa-01 on adhesion properties is that the cell lines show different levels of integrin receptors for fibronectin. To test this hypothesis, we analyzed the integrin expression level on fibroblasts (BJ), a highly invasive/low differentiated (SCC25) and a low invasive/highly differentiated (Cal27) OSCC cell line (Fig 3). We observed that the low invasive/high differentiated OSCC cell line (Cal27) presents only low levels of αv subunit, which might explain the poor migratory performance observed on fibronectin [8]. However, fibroblasts showed high levels of all fibronectin-related integrin subunits, which corroborates to the fast single cell migration phenotype. When we analyzed the integrin levels of the highly invasive OSCC cell line, besides the high level of alpha-subunits, these cells show low levels of β1 and high levels of β3 subunits, which indicates that the migration process of this epithelial-derived tumor cell line on fibronectin relies mostly on β3 activity. Since DisBa-01 is an RGD disintegrin, this result suggests that DisBa-01 could be selectively acting on αvβ3 integrin of OSCC cells. Since highly invasive OSCC cells migrate in a collective way in matrigel but individually in fibronectin [8], we also tested if DisBa-01 could inhibit matrigel invasion. In fact, DisBa-01 (1 and 2 μM) inhibited OSCC invasion (approx. 40 and 50%, respectively) through matrigel (S1 Fig), thus indicating that this disintegrin can inhibit both forms of migration.
To further analyze this result and confirm that the effects of DisBa-01 on migration and adhesion of OSCC cells were caused by the interaction of the disintegrin with the αvβ3 and not α5β1integrin, the main receptors involved in fibronectin binding [15], the binding between the disintegrin and purified integrins (αvβ3, α5β1) were analyzed by SPR. The interaction between DisBa-01 and the αvβ3 integrin was about 100x higher than that for α5β1integrin (Kd 7.62 x10–5M) indicating a stronger affinity of the disintegrin for the αvβ3integrin. This difference can also be seen in Fig 4.
β3 overexpression recovered DisBa-01 effects
DisBa-01 interacts with αvβ3 integrins [26], suggesting that the interaction between DisBa-01 and integrins impairs the migratory activity of OSCC cells. To test this hypothesis, OSCCs were transfected with β3 subunit, plated on fibronectin-covered dishes in the presence/absence of DisBa-01, and migration properties were assessed. Expression levels of two plasmid concentrations for β3 subunit had shown that the lower concentration had little effect whereas the higher concentration, the chosen one, was closer to the BJ integrin levels (Fig 5A, S4 Movie). It was observed that the overexpression of β3 subunit restored the migration speed and directionality of cells plated in the presence of DisBa-01. Adhesion and protrusion areas of cells overexpressing β3 integrin with or without DisBa-01 were assessed both by immunostaining for paxillin and co-transfection with paxillin-mkousing confocal and TIRF microscopy, respectively. Overexpression of β3 integrin rescued cells from a phenotype of larger adhesions and protrusions and slower migration (Fig 5 and S5 Movie) such as the phenotype induced byDisBa-01 (2μM), which corroborates with the hypothesis that the inhibition of β3 integrin by DisBa-01is the probable mechanism by which DisBa-01 impairs the migration properties of OSCC cells.
Discussion
Tumor metastasis is a major cause of clinical failure in cancer treatment and might be influenced by extrinsic factors, such as the composition of the environment, as well as by intrinsic migratory properties of tumor cells. Also, tumor cell plasticity is a response to micro environmental changes and often influences tumor progression, invasion and resistance to therapy [33, 34]. Alterations in matrix density, pliability, and composition, the nature of the adhesion receptors such as integrins or cadherins, respectively, and expression of cytoskeletal adaptor proteins can lead to interconvertible changes on migration mode depending on each cell intrinsic capacities [8, 34]. Therefore, the blockage of the interaction of tumor cells with the extracellular matrix is an interesting alternative for complementary therapies. For instance, cilengitide is a RGD cyclic pentapeptide that selectively inhibits of αvβ5 and αvβ3 integrins and results from phase 2 trials show an antitumor activity against glioblastoma although it failed to improve patient outcome in phase 3 trials [35–36]. Despite this fact, targeting integrins remains an interesting strategy to disrupt cell-matrix interactions in cancer therapy, according to the authors.
We demonstrated that DisBa-01, an RGD disintegrin, present on media or substrate, was able to significantly decrease cell migration and cell directionality of highly invasive OSCC, on fibronectin coated dishes but it did not affect fibroblasts. Since soluble and immobilized disintegrin forms triggered opposite results in the past [37], both forms were tested. Migration initiates with biochemical or mechanical cues from the extracellular environment [11, 38]. As demonstrated by previous studies, fibronectin induces migration of different cells lines including low and highly differentiated OSCC cells [8, 39–40]. One interesting finding was that OSCC cells in the presence of DisBa-01 migrated in a similar fashion of low invasive OSCC cells, Cal27, also plated over fibronectin. Cells moved in circles and in a collective way, indicating loss of directionality and a change on the migration mode that leads toward a less aggressive cell migration phenotype [8]. Another small RGD containing motif disintegrin, eristostatin, was reported to decrease migration speed in a wound healing assay using fibronectin coated plates and melanoma cells. Although it is not mentioned on the report, it is possible to notice impairments on cells directionality and changes on cells morphology especially on the highly invasive melanoma cell c8161 time-lapse videos [18]. According to Missirlis et al [39] the inhibition of αvβ3 or α5β1 integrins, both on fibronectin coated surfaces caused cells to lose their directionality, but with increased migration speed [39]. Cilengitide was also able to disrupt cell migration, in time-lapse assays, decreasing by ~40%the migration speed in glioblastoma-derived cells, although cells were not plated over fibronectin [41].
A possible mechanism of action for the impairment of cell migration by DisBa-01 is the modulation of the adhesions. In order to better understand our results on the effects of DisBa-01 on OSCC migration, we looked deeper into cell adhesion dynamics and morphology. Fast migratory cells, such as leucocytes, are characterized by small and rapidly turning over adhesions while slow adherent migratory cell possesses persistent adhesions that mature into larger and elongated focal complexes [11, 40]. Highly invasive OSCC cells have small and dynamic adhesions when plated on fibronectin, as it was already demonstrated [38]. Adhesion and protrusion sizes were measured and when DisBa-01 was added to the cells, adhesions became larger, with a higher rate of maturation and some instability could be noticed on membrane protrusions. Blocking of α5β1but not αvβ3 integrin by a specific ligand also increased adhesion sizes [39]. So adhesions function as anchors that respond to different stimuli and forces from the ECM and/or cytoskeleton altering its shape, size and dynamics according to the environment during the migration process [42–44].
Variations in integrin expression could lead to different migratory phenotypes and how cells are affected by DisBa-01. For instance, the blockage of β3 subunit by DisBa-01 did not affect the migration performance of fibroblasts probably due to the high amounts of both β1 and β3 subunits present in this cell. However, our results on the migration speed inhibition of OSCC could be due to DisBa-01 interaction with αvβ3 integrin that leaves cells with no proper traction forces to migrate, although they are still adherent, since β1 subunit is present in very limited amount. Moreover, β1 subunit has been characterized for promoting cell migration with no directionality on fibronectin coated surfaces, [45] such as the motile behavior seen on highly aggressive OSCC cell line in the presence of DisBa-01. This hypothesis was confirmed by the higher affinity that DisBa-01 has for αvβ3 integrin, as Ramos et al [26] first demonstrated and confirmed here, and its lower affinity for the integrin α5β1. Finally, the overexpression of β3 subunit on OSCC rescued the migratory phenotype once altered by DisBa-01 supporting the hypothesis that the major receptor of DisBa-01 is the integrin αvβ3. These data show that, during invasion, epithelial-derived tumor cells switch the expression of integrins, favoring those which interact with the connective tissue, and that the specific blockage of these receptors, might impair the invasive process. On the other hand, silencing of αvβ3 integrin was recently demonstrated to decrease migration of both malignant glioma and triple negative breast cancer cells [46, 47]. These studies are in complete agreement with our results.
To find new therapies for oral cancers, we showed that an RGD disintegrin changes the migration behavior of an aggressive cancer cell by decreasing its migration speed, directionality and changing adhesion phenotype upon αvβ3 integrin binding. This interesting phenomenon highlights cell plasticity and turning it to our own benefit could be an achievable way to fight against invasion and metastasis.
Supporting information
Data Availability
All relevant data are within the paper and its Supporting Information files.
Funding Statement
This work was supported by National Institute of Health [NIH, GM23244], Alan R. Horwitz, https://www.nih.gov; FAPESP 2013/00798-2, HSS Araujo, www.fapesp.br; CNPq 140130/2012-8, CF Montenegro, 308096/2013-4 HSS Araujo, www.cnpq.br. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
References
- 1.Scully C, Bagan J. Oral squamous cell carcinoma overview. Oral Oncol 2009;45: 301–8. doi: 10.1016/j.oraloncology.2009.01.004 [DOI] [PubMed] [Google Scholar]
- 2.Silva SD Da, Ferlito A, Takes RP, Brakenhoff RH, Valentin MD, Woolgar JA, et al. Advances and applications of oral cancer basic research. Oral Oncol 2011; 47:783–91. doi: 10.1016/j.oraloncology.2011.07.004 [DOI] [PubMed] [Google Scholar]
- 3.Gleber-Netto FO, Braakhuis BJM, Triantafyllou A, Takes RP, Kelner N, Rodrigo JP, et al. Molecular events in relapsed oral squamous cell carcinoma: Recurrence vs secondary primary tumor q. Oral Oncol 2015; 51:738–44. doi: 10.1016/j.oraloncology.2015.04.016 [DOI] [PubMed] [Google Scholar]
- 4.Alizadeh AM, Shiri S, Farsinejad S. Metastasis review: from bench to bedside. vol. 35 2014; 35: 8483–523. doi: 10.1007/s13277-014-2421-z [DOI] [PubMed] [Google Scholar]
- 5.Friedl P, Alexander S. Cancer invasion and the microenvironment: Plasticity and reciprocity. Cell 2011; 147:992–1009. doi: 10.1016/j.cell.2011.11.016 [DOI] [PubMed] [Google Scholar]
- 6.Kosmehl H, Berndt a, Strassburger S, Borsi L, Rousselle P, Mandel U, et al. Distribution of laminin and fibronectin isoforms in oral mucosa and oral squamous cell carcinoma. Br J Cancer 1999; 81: 1071–9. doi: 10.1038/sj.bjc.6690809 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7.Harada T, Shinohara M, Nakamura S, Oka M. An immunohistochemical study of the extracellular matrix in oral squamous cell carcinoma and its association with invasive and metastatic potential. Virchows Arch 1994;424:257–66. [DOI] [PubMed] [Google Scholar]
- 8.De Oliveira Ramos G, Bernardi L, Lauxen I, Filho MSA, Horwitz AR, Lamers ML. Fibronectin modulates cell adhesion and signaling to promote single cell migration of highly invasive oral squamous cell carcinoma. PLoS One 2016; 11:1–18. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9.Vicente-Manzanares M, Horwitz A. R. Adhesion dynamics at a glance. J Cell Sci 2011; 124:3923–7. doi: 10.1242/jcs.095653 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10.Hynes RO. Integrins: Bidirectional, Allosteric Signaling Machines In their roles as major adhesion receptors, Cell 2002; 110: 673–87. [DOI] [PubMed] [Google Scholar]
- 11.Levy JR, Holzbaur ELF, Parsons JT, Horwitz AR, Schwartz M a, Larson DR, et al. Cell adhesion: integrating cytoskeletal dynamics and cellular tension. Mol Cell 2010; 11: 633–43. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12.Giancotti FG, Ruoslahti E. Integrin signaling. Science 1999; 285: 1028–32. [DOI] [PubMed] [Google Scholar]
- 13.Desgrosellier J, David C. Integrins in cancer: biological implications in therapeutic opportunities. Cancer, Nat Rev 2015; 10:9–22. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 14.Schiller HB, Hermann M-R, Polleux J, Vignaud T, Zanivan S, Friedel CC, et al. beta1- and alphav-class integrins cooperate to regulate myosin II during rigidity sensing of fibronectin-based microenvironments. Nat Cell Biol 2013; 15:625–36. doi: 10.1038/ncb2747 [DOI] [PubMed] [Google Scholar]
- 15.Danen EHJ, Sonneveld P, Brakebusch C, Fässler R, Sonnenberg A. The fibronectin-binding integrins α5β1 and αvβ3 differentially modulate RhoA-GTP loading, organization of cell matrix adhesions, and fibronectin fibrillogenesis. J Cell Biol 2002; 159:1071–86. doi: 10.1083/jcb.200205014 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 16.Morgan MR, Byron A, Humphries MJ, Bass MD. Critical Review Giving off Mixed Signals—Distinct Functions of a 5 b 1 and a V b 3 Integrins in Regulating Cell Behaviour 2009; 61: 731–8. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17.Calvete JJ. The continuing saga of snake venom disintegrins. Toxicon 2013; 62:40–9. doi: 10.1016/j.toxicon.2012.09.005 [DOI] [PubMed] [Google Scholar]
- 18.Tian J, Paquette-Straub C, Sage EH, Funk SE, Patel V, Galileo D, et al. Inhibition of melanoma cell motility by the snake venom disintegrin eristostatin. Toxicon 2007; 49: 899–908. doi: 10.1016/j.toxicon.2006.12.013 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 19.Lucena S, Castro R, Lundin C, Hofstetter A, Alaniz A, Suntravat M, et al. Inhibition of pancreatic tumoral cells by snake venom disintegrins. Toxicon 2015; 93: 136–43. doi: 10.1016/j.toxicon.2014.11.228 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 20.Olfa K-Z, José L, Salma D, Amine B, Najet SA, Nicolas A, et al. Lebestatin, a disintegrin from Macrovipera venom, inhibits integrin-mediated cell adhesion, migration and angiogenesis. Lab Invest 2005; 85: 1507–16. doi: 10.1038/labinvest.3700350 [DOI] [PubMed] [Google Scholar]
- 21.Coelho AL, de Freitas MS, Oliveira-Carvalho AL, Moura-Neto V, Zingali RB, Barja-Fidalgo C. Effects of jarastatin, a novel snake venom disintegrin, on neutrophil migration and actin cytoskeleton dynamics. Exp Cell Res 1999; 251: 379–87. doi: 10.1006/excr.1999.4583 [DOI] [PubMed] [Google Scholar]
- 22.Huang TF. What have snakes taught us about integrins? Cell Mol Life Sci 1998; 54: 527–40. doi: 10.1007/s000180050181 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 23.Gan Z, Gouldg RJ, Jacobs JW, Friedman PA, V MAP. Echis carinatus. J Biol Chemol Chem 1988; 263: 19827–32. [PubMed] [Google Scholar]
- 24.Selistre-de-Araujo HS, Pontes CLS, Montenegro CF, Martin ACBM. Snake venom disintegrins and cell migration. Toxins (Basel) 2010;2:2606–21. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 25.Cassini-Vieira P, Deconte SR amos, Tomiosso TC arla, Campos PP eixoto, Montenegro C de F, Selistre-de-Araújo HS obreiro, et al. DisBa-01 inhibits angiogenesis, inflammation and fibrogenesis of sponge-induced-fibrovascular tissue in mice. Toxicon 2014; 92:81–9. doi: 10.1016/j.toxicon.2014.10.007 [DOI] [PubMed] [Google Scholar]
- 26.Ramos OHP, Kauskot A, Cominetti MR, Bechyne I, Salla Pontes CL, Chareyre F, et al. A novel αvβ3-blocking disintegrin containing the RGD motive, DisBa-01, inhibits bFGF-induced angiogenesis and melanoma metastasis. Clin Exp Metastasis 2008;25:53–64. doi: 10.1007/s10585-007-9101-y [DOI] [PubMed] [Google Scholar]
- 27.Montenegro CF, Salla-Pontes CL, Ribeiro JU, MacHado AZ, Ramos RF, Figueiredo CC, et al. Blocking αvβ3 integrin by a recombinant RGD disintegrin impairs VEGF signaling in endothelial cells. Biochimie 2012; 94: 1812–20. doi: 10.1016/j.biochi.2012.04.020 [DOI] [PubMed] [Google Scholar]
- 28.Colley HE, Hearnden V, Jones a V, Weinreb PH, Violette SM, Macneil S, et al. Development of tissue-engineered models of oral dysplasia and early invasive oral squamous cell carcinoma. Br J Cancer 2011; 105: 1582–92. doi: 10.1038/bjc.2011.403 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 29.Laukaitis CM, Webb DJ, Donais K, Horwitz AF. Differential dynamics of α5 integrin, paxillin, and α-actinin during formation and disassembly of adhesions in migrating cells. J Cell Biol 2001; 153:1427–40. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 30.Lamers ML, Almeida MES, Vicente-Manzanares M, Horwitz AF, Santos MF. High glucose-mediated oxidative stress impairs cell migration. PLoS One 2011;6:1–9. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 31.Choi CK, Vicente-Manzanares M, Zareno J, Whitmore LA, Mogilner A, Horwitz AR. Actin and α-actinin orchestrate the assembly and maturation of nascent adhesions in a myosin II motor-independent manner. Nat Cell Biol 2008; 10:1039–50. doi: 10.1038/ncb1763 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 32.Leavesley G.D.; Wayner E.A.; Cheresh D.A. DI. F. Requirement of the Integrin β3 subunit for carcinoma cell spreading or migration on vitronectin and fibronectin. J Cell Biol 1992; 117: 1101–7. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 33.Bissell MJ, Hines WC. Why don’t we get more cancer? A proposed role of the microenvironment in restraining cancer progression. Nat Med 2011; 17: 320–9. doi: 10.1038/nm.2328 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 34.Friedl P, Wolf K. Plasticity of cell migration: a multiscale tuning model. J Cell Biol 2010; 188: 11–9. doi: 10.1083/jcb.200909003 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 35.Stupp R, Hegi ME, Gorlia T, Erridge SC, Perry J, Hong Y-K, et al. Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071–22072 study): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol 2014; 15: 1100–8. doi: 10.1016/S1470-2045(14)70379-1 [DOI] [PubMed] [Google Scholar]
- 36.Reardon DA, Cheresh D. Cilengitide: a prototypic integrin inhibitor for the treatment of glioblastoma and other malignancies. Genes Cancer 2011; 2: 1159–65. doi: 10.1177/1947601912450586 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 37.Marcinkiewicz C. Applications of snake venom components to modulate integrin activities in cell–matrix interactions. Int J Biochem Cell Biol 2013; 45: 1974–86. doi: 10.1016/j.biocel.2013.06.009 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 38.Friedl P, Wolf K. Tumour-cell invasion and migration: diversity and escape mechanisms. Nat Rev Cancer 2003; 3: 362–74. doi: 10.1038/nrc1075 [DOI] [PubMed] [Google Scholar]
- 39.Missirlis D, Haraszti T, Scheele C v C, Wiegand T, Diaz C, Neubauer S, et al. Substrate engagement of integrins α5β1 and αvβ3 is necessary, but not sufficient, for high directional persistence in migration on fibronectin. Sci Rep 2016; 6: 23258 doi: 10.1038/srep23258 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 40.Chen L, Vicente-Manzanares M, Potvin-Trottier L, Wiseman PW, Horwitz AR. The integrin-ligand interaction regulates adhesion and migration through a molecular clutch. PLoS One 2012; 7: e40202 doi: 10.1371/journal.pone.0040202 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 41.Anderson HJ, Galileo DS. Small-molecule inhibitors of FGFR, integrins and FAK selectively decrease L1CAM-stimulated glioblastoma cell motility and proliferation. Cell Oncol 2016; 39: 229–42. [DOI] [PubMed] [Google Scholar]
- 42.Oakes PW, Gardel ML. Stressing the limits of focal adhesion mechanosensitivity. Curr Opin Cell Biol 2014; 30: 68–73. doi: 10.1016/j.ceb.2014.06.003 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 43.Barnhart EL, Lee KC, Keren K, Mogilner A, Theriot JA. An adhesion-dependent switch between mechanisms that determine motile cell shape. PLoS Biol 2011; 9: e1001059 doi: 10.1371/journal.pbio.1001059 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 44.Di Cio S, Gautrot JE. Cell sensing of physical properties at the nanoscale: Mechanisms and control of cell adhesion and phenotype. Acta Biomater 2016; 30:26–48. doi: 10.1016/j.actbio.2015.11.027 [DOI] [PubMed] [Google Scholar]
- 45.Danen EHJ, Van Rheenen J, Franken W, Huveneers S, Sonneveld P, Jalink K, et al. Integrins control motile strategy through a Rho-cofilin pathway. J Cell Biol 2005; 169: 515–26. doi: 10.1083/jcb.200412081 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 46.Parvani JG, Gujrati MD, Mack MA, Schiemann WP, Lu ZR. Silencing β3 integrin by targeted ECO/siRNA nanoparticles inhibits EMT and metastasis of triple-negative breast cancer. Cancer Res 2015; 75(11): 2316–25. doi: 10.1158/0008-5472.CAN-14-3485 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 47.Christmann M, Diesler K, Majhen D, Steigerwald C, Berte N, Freund H, et al. Integrin αvβ3 silencing sensitizes malignant glioma cells to temozolomide by suppression of homologous recombination repair. Oncotarget 2016; [Epub ahead of print]. [DOI] [PMC free article] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Supplementary Materials
Data Availability Statement
All relevant data are within the paper and its Supporting Information files.